China Pharma Holdings, Inc. (CPHI)
USD 0.17
(-9.78%)
USD 0.17
(-9.78%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.01 Million USD | -33.2% |
| 2022 | 13.49 Million USD | -18.87% |
| 2021 | 16.63 Million USD | 26.83% |
| 2020 | 13.11 Million USD | 0.89% |
| 2019 | 12.99 Million USD | -14.37% |
| 2018 | 15.17 Million USD | -10.09% |
| 2017 | 16.88 Million USD | -13.92% |
| 2016 | 19.61 Million USD | -20.22% |
| 2015 | 24.58 Million USD | -4.83% |
| 2014 | 25.82 Million USD | 4.71% |
| 2013 | 24.66 Million USD | 67.53% |
| 2012 | 14.72 Million USD | 5.86% |
| 2011 | 13.9 Million USD | 0.68% |
| 2010 | 13.81 Million USD | 31.0% |
| 2009 | 10.54 Million USD | 88.18% |
| 2008 | 5.6 Million USD | 42.05% |
| 2007 | 3.94 Million USD | -48.53% |
| 2006 | 7.66 Million USD | 32.1% |
| 2005 | 5.8 Million USD | 8381.55% |
| 2004 | 68.4 Thousand USD | -93.38% |
| 2003 | 1.03 Million USD | 4.09% |
| 2002 | 992.01 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 7.89 Million USD | -12.38% |
| 2024 Q2 | 6.85 Million USD | -13.24% |
| 2023 Q3 | 9.24 Million USD | -18.59% |
| 2023 Q1 | 12.68 Million USD | -5.98% |
| 2023 Q2 | 11.35 Million USD | -10.52% |
| 2023 FY | 9.01 Million USD | -33.2% |
| 2023 Q4 | 9.01 Million USD | -2.46% |
| 2022 FY | 13.49 Million USD | -18.87% |
| 2022 Q4 | 13.49 Million USD | 0.94% |
| 2022 Q2 | 13.89 Million USD | -11.52% |
| 2022 Q1 | 15.7 Million USD | -5.58% |
| 2022 Q3 | 13.36 Million USD | -3.78% |
| 2021 Q1 | 12.68 Million USD | -3.29% |
| 2021 Q2 | 13.41 Million USD | 5.82% |
| 2021 Q3 | 11.32 Million USD | -15.58% |
| 2021 Q4 | 16.63 Million USD | 46.82% |
| 2021 FY | 16.63 Million USD | 26.83% |
| 2020 Q3 | 13.26 Million USD | -10.16% |
| 2020 FY | 13.11 Million USD | 0.89% |
| 2020 Q1 | 14.05 Million USD | 8.14% |
| 2020 Q2 | 14.76 Million USD | 5.05% |
| 2020 Q4 | 13.11 Million USD | -1.15% |
| 2019 Q4 | 12.99 Million USD | 3.62% |
| 2019 Q1 | 14.62 Million USD | -3.65% |
| 2019 FY | 12.99 Million USD | -14.37% |
| 2019 Q2 | 14.06 Million USD | -3.84% |
| 2019 Q3 | 12.54 Million USD | -10.8% |
| 2018 Q3 | 14.9 Million USD | -13.78% |
| 2018 Q2 | 17.28 Million USD | -2.22% |
| 2018 FY | 15.17 Million USD | -10.09% |
| 2018 Q1 | 17.67 Million USD | 4.7% |
| 2018 Q4 | 15.17 Million USD | 1.86% |
| 2017 Q2 | 19.98 Million USD | 1.32% |
| 2017 Q1 | 19.72 Million USD | 0.56% |
| 2017 FY | 16.88 Million USD | -13.92% |
| 2017 Q4 | 16.88 Million USD | -6.02% |
| 2017 Q3 | 17.96 Million USD | -10.1% |
| 2016 Q2 | 25.01 Million USD | -1.76% |
| 2016 Q1 | 25.46 Million USD | 3.59% |
| 2016 FY | 19.61 Million USD | -20.22% |
| 2016 Q4 | 19.61 Million USD | -12.73% |
| 2016 Q3 | 22.47 Million USD | -10.17% |
| 2015 FY | 24.58 Million USD | -4.83% |
| 2015 Q4 | 24.58 Million USD | -4.98% |
| 2015 Q3 | 25.86 Million USD | -1.4% |
| 2015 Q2 | 26.23 Million USD | -0.61% |
| 2015 Q1 | 26.39 Million USD | 2.2% |
| 2014 Q2 | 25.07 Million USD | 0.7% |
| 2014 Q4 | 25.82 Million USD | -0.19% |
| 2014 FY | 25.82 Million USD | 4.71% |
| 2014 Q1 | 24.9 Million USD | 0.97% |
| 2014 Q3 | 25.87 Million USD | 3.18% |
| 2013 Q1 | 12.73 Million USD | -13.5% |
| 2013 Q4 | 24.66 Million USD | 25.66% |
| 2013 FY | 24.66 Million USD | 67.53% |
| 2013 Q3 | 19.62 Million USD | 33.95% |
| 2013 Q2 | 14.65 Million USD | 15.06% |
| 2012 FY | 14.72 Million USD | 5.86% |
| 2012 Q1 | 17.41 Million USD | 25.19% |
| 2012 Q2 | 16.72 Million USD | -3.96% |
| 2012 Q3 | 16.71 Million USD | -0.06% |
| 2012 Q4 | 14.72 Million USD | -11.9% |
| 2011 Q4 | 13.9 Million USD | 5.36% |
| 2011 Q2 | 12.39 Million USD | -4.64% |
| 2011 Q3 | 13.19 Million USD | 6.46% |
| 2011 Q1 | 13 Million USD | -5.87% |
| 2011 FY | 13.9 Million USD | 0.68% |
| 2010 Q3 | 11.03 Million USD | -12.97% |
| 2010 Q2 | 12.67 Million USD | 17.18% |
| 2010 Q1 | 10.81 Million USD | 2.59% |
| 2010 FY | 13.81 Million USD | 31.0% |
| 2010 Q4 | 13.81 Million USD | 25.21% |
| 2009 FY | 10.54 Million USD | 88.18% |
| 2009 Q1 | 6.79 Million USD | 21.22% |
| 2009 Q2 | 8 Million USD | 17.82% |
| 2009 Q3 | 10.13 Million USD | 26.63% |
| 2009 Q4 | 10.54 Million USD | 4.05% |
| 2008 FY | 5.6 Million USD | 42.05% |
| 2008 Q2 | 5.01 Million USD | 4.6% |
| 2008 Q3 | 2.34 Million USD | -53.3% |
| 2008 Q4 | 5.6 Million USD | 139.35% |
| 2008 Q1 | 4.79 Million USD | 21.5% |
| 2007 Q4 | 3.94 Million USD | -52.06% |
| 2007 FY | 3.94 Million USD | -48.53% |
| 2007 Q3 | 8.22 Million USD | 0.43% |
| 2007 Q2 | 8.19 Million USD | 1.72% |
| 2007 Q1 | 8.05 Million USD | 5.11% |
| 2006 FY | 7.66 Million USD | 32.1% |
| 2006 Q4 | 7.66 Million USD | -8.88% |
| 2006 Q3 | 8.41 Million USD | 32.66% |
| 2006 Q2 | 6.34 Million USD | -8.18% |
| 2006 Q1 | 6.9 Million USD | 0.0% |
| 2005 Q2 | 4473.00 USD | -96.62% |
| 2005 Q3 | 13.84 Million USD | 309495.95% |
| 2005 Q1 | 132.16 Thousand USD | 36.98% |
| 2005 FY | 5.8 Million USD | 8381.55% |
| 2004 Q4 | 96.48 Thousand USD | 21.93% |
| 2004 FY | 68.4 Thousand USD | -93.38% |
| 2004 Q1 | 43.97 Thousand USD | 0.0% |
| 2004 Q2 | 68.4 Thousand USD | 55.54% |
| 2004 Q3 | 79.13 Thousand USD | 15.68% |
| 2003 Q1 | 1.05 Million USD | 3.41% |
| 2003 FY | 1.03 Million USD | 4.09% |
| 2003 Q2 | 1.03 Million USD | -2.07% |
| 2003 Q4 | 43.97 Thousand USD | 0.69% |
| 2003 Q3 | 43.67 Thousand USD | -95.77% |
| 2002 Q1 | 985.5 Thousand USD | 28.53% |
| 2002 Q2 | 992.01 Thousand USD | 0.66% |
| 2002 Q3 | 991.22 Thousand USD | -0.08% |
| 2002 Q4 | 1.01 Million USD | 2.87% |
| 2002 FY | 992.01 Thousand USD | 0.0% |
| 2001 Q4 | 766.76 Thousand USD | 11.59% |
| 2001 Q3 | 687.13 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| cbdMD, Inc. | 7.16 Million USD | -25.832% |
| cbdMD, Inc. | 7.16 Million USD | -25.832% |
| Zomedica Corp. | 13.18 Million USD | 31.604% |